Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Indivior issued a press release on May 4, 2026 under Regulation FD.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Indivior issued a press release on May 4, 2026 under Regulation FD
- Investor-relevant details are contained in the referenced press release exhibit
Item 8.01 · Other Events
- $175 million accelerated share repurchase under Indivior’s existing $400 million authorization
- Initial delivery of 3,717,473 shares, reducing shares outstanding immediately
- Final shares based on volume-weighted average price less a discount during the transaction
- Settlement by June 22, 2026, with potential additional shares, share delivery, or cash payment
Item EX-99.1 · Exhibit EX-99.1
- $175 million accelerated share repurchase with Barclays, funded upfront under existing $400 million authorization
- Initial delivery of 3,717,473 shares, reducing shares outstanding and potentially increasing per-share metrics
- Final repurchased shares tied to volume-weighted average price less discount, with settlement by end-June 2026
- Remaining $100 million authorization available for additional repurchases, subject to market conditions
- No expected impact on previously issued financial guidance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.